Gossamer Bio Inc
GOSS
Company Profile
Business description
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension).
Contact
3115 Merryfield Row
Suite 120
San DiegoCA92121
USAT: +1 858 684-1300
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
162
Stocks News & Analysis
stocks
ASX major bank drives strong quarterly profit
Profit momentum remains robust yet shares overvalued.
stocks
Ask the analyst: What to expect in earnings season?
The key metrics that matter this earnings season.
stocks
ASX healthcare share remains undervalued ahead of earnings
Margin recovery remains the key driver for this ASX healthcare share.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,035.00 | 2.70 | 0.03% |
| CAC 40 | 8,406.06 | 33.78 | 0.40% |
| DAX 40 | 25,361.03 | 262.03 | 1.04% |
| Dow JONES (US) | 52,210.08 | 262.83 | 0.51% |
| FTSE 100 | 10,781.75 | 45.52 | 0.42% |
| HKSE | 25,207.18 | 243.95 | 0.98% |
| NASDAQ | 24,932.08 | 43.74 | -0.18% |
| Nikkei 225 | 62,796.37 | 2,134.82 | -3.29% |
| NZX 50 Index | 13,838.06 | 12.63 | -0.09% |
| S&P 500 | 7,413.18 | 1.20 | 0.02% |
| S&P/ASX 200 | 8,865.10 | 2.90 | 0.03% |
| SSE Composite Index | 3,858.25 | 44.05 | 1.15% |